Sanjivani Paranteral Limited Q2 FY26 Concall Decoded: Revenue fell 14.5%, but management is busy selling a ₹100-crore IV dream and blaming geopolitics

---

1. Opening Hook

Just when pharma investors thought “defensive” meant safe, Sanjivani Paranteral reminded everyone that even syringes aren’t immune to riots, regulators, and random Latin American audits. Q2 FY26 arrived with a revenue drop, margin pain, and a management commentary that read like a global risk manual—Nepal unrest here, LatAm scrutiny there, Africa on pause, antibiotics losing relevance everywhere.

But don’t worry, says management—this was just a “temporary aberration.” Apparently, the real blockbuster starts in Q3, when shipments magically clear, IV fluids gush cash, and Europe discovers nutraceuticals packed in Prague.

Is this a classic pharma hiccup… or another case of next-quarter syndrome?
Stick around—because the promises get bigger, the numbers get bolder, and FY27 has already been declared a victory lap.

---

2. At a Glance

• Revenue ₹15.5 cr (↓14.5%) – Export gods were angry; management lit regulatory incense.
• EBITDA ₹2.4 cr (↓25.6%) – Operating leverage worked… in reverse.
• EBITDA margin 15.5% (↓240 bps) – Costs didn’t get the slowdown memo.
• PAT ₹1.6 cr (↓28.5%) – Profit followed revenue, loyally downhill.
• Exports 81.6% of sales – Global footprint, global headaches included.

---

3. Management’s Key Commentary (Decoded)

“We are a WHO-GMP certified company exporting to over 25 countries.”
(Translation: Quality badge activated; now please ignore this quarter 😏)

“Macro uncertainties were much lower in Q2.”
(Except riots, audits, unrest, and delayed approvals—minor details)

“Nepal unrest impacted ₹1 crore of orders.”
(Yes, geopolitics hit your EPS)

“LatAm scrutiny due to other Indian exporters slowed dispatches.”
(Guilty by nationality, welcome to pharma exports)

“We held shipments to avoid inventory getting stuck.”
(We chose pain now instead of disaster later)

“SPL Infusion will start contributing from Q3.”
(The saviour plant enters stage right 🚰)

“The IV plant can do ₹90–110 cr annually.”
(PowerPoint capacity utilization unlocked)

“Antibiotics are declining globally due to resistance.”
(Good thing we say exposure is only 7–8%)

---

4. Numbers Decoded

Source table

Metric	Q2 FY26	YoY Trend	What It Really Means
Revenue	₹15.5 cr	↓14.5%	Shipments delayed, not demand dead
EBITDA	₹2.4 cr	↓25.6%	Operating leverage turned